Literature DB >> 18165625

Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.

Giulio Metro, Isabella Sperduti, Michelangelo Russillo, Michele Milella, Francesco Cognetti, Alessandra Fabi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18165625     DOI： 10.1634/theoncologist.12-12-1467

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  8 in total

1.  Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy.

Authors:  Renata Duchnowska; Wojciech Biernat; Barbara Szostakiewicz; Jeff Sperinde; Fanny Piette; Mojgan Haddad; Agnes Paquet; Yolanda Lie; Bogumiła Czartoryska-Arłukowicz; Piotr Wysocki; Tomasz Jankowski; Barbara Radecka; Małgorzata Foszczynska-Kłoda; Maria Litwiniuk; Sylwia Debska; Jodi Weidler; Weidong Huang; Marc Buyse; Michael Bates; Jacek Jassem
Journal:  Oncologist       Date:  2012-01-10

2.  HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis.

Authors:  Anders W Erickson; Farinaz Ghodrati; Steven Habbous; Katarzyna J Jerzak; Arjun Sahgal; Manmeet S Ahluwalia; Sunit Das
Journal:  Neurooncol Adv       Date:  2020-10-14

3.  An exploration of the clinical progression models of osimertinib in the treatment of advanced EGFR-mutant non-small cell lung cancer.

Authors:  Yue Shi; Yingying Jiang; Banzhou Pan; Zihan Wang; Hang Li; Yuxin Ma; Yilin Liu; Kang He; Zhitong Wang; Jianwei Lu; Meiqi Shi; Bo Shen; Guoren Zhou; Rong Yin; Antonio Rossi; Kentaro Ito; Mariacarmela Santarpia; Sang-Won Um; Xiaohua Wang; Cheng Chen; Jifeng Feng
Journal:  Transl Lung Cancer Res       Date:  2022-05

4.  Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.

Authors:  Andrew J Weickhardt; Benjamin Scheier; Joseph Malachy Burke; Gregory Gan; Xian Lu; Paul A Bunn; Dara L Aisner; Laurie E Gaspar; Brian D Kavanagh; Robert C Doebele; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609

5.  Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema.

Authors:  Julie A Carlson; Zohra Nooruddin; Chad Rusthoven; Anthony Elias; Virginia F Borges; Jennifer R Diamond; Brian Kavanagh; Peter Kabos
Journal:  Neuro Oncol       Date:  2014-07       Impact factor: 12.300

Review 6.  Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier.

Authors:  Lois A Lampson
Journal:  MAbs       Date:  2011-03-01       Impact factor: 5.857

Review 7.  First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?

Authors:  Alessandra Fabi; Paola Malaguti; Sabrina Vari; Francesco Cognetti
Journal:  J Exp Clin Cancer Res       Date:  2016-06-30

8.  Incidence of central nervous system metastases in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with trastuzumab: A meta-analysis.

Authors:  Xue Bai; Xue Lin; Jin Song; Jia-Han Chang; Li-Li Han; Cibo Fan
Journal:  Clinics (Sao Paulo)       Date:  2021-08-16       Impact factor: 2.365
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.